DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Triostat (Liothyronine Sodium Injection) - Summary

 
 



BOX WARNING

Drugs with thyroid hormone activity, alone or together with other therapeutic agents, have been used for the treatment of obesity. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects.

 

TRIOSTAT SUMMARY

Triostat (liothyronine sodium injection) (T3) contains liothyronine (L-triiodothyronine or L-T3), a synthetic form of a natural thyroid hormone, as the sodium salt.

Triostat (liothyronine sodium injection) (T3) is indicated in the treatment of myxedema coma/precoma.

Triostat can be used in patients allergic to desiccated thyroid or thyroid extract derived from pork or beef.


See all Triostat indications & dosage >>

NEWS HIGHLIGHTS

Published Studies Related to Triostat (Liothyronine)

Metabolic effects of liothyronine therapy in hypothyroidism: a randomized, double-blind, crossover trial of liothyronine versus levothyroxine. [2011]
CONCLUSIONS: The substitution of L-T(3) for L-T(4) at equivalent doses (relative

The pharmacodynamic equivalence of levothyroxine and liothyronine: a randomized, double blind, cross-over study in thyroidectomized patients. [2010.05]
CONTEXT: The substitution of liothyronine (L-T3) for levothyroxine (L-T4) is commonly employed during thyroid hormone (TH) withdrawal in preparation for diagnostic and therapeutic interventions on thyroid cancer patients. Presently, only limited data are available on the L-T3 for L-T4 therapeutic substitution. Objective To characterize the pharmcodynamic equivalence of L-T3 and L-T4... CONCLUSIONS: This is the first study addressing the equivalency between L-T3 and L-T4 therapy measured by baseline and TRH-stimulated TSH. The therapeutic substitution of L-T3 for L-T4 was achieved at approximately 1:3 ratio.

The pharmacodynamic equivalence of levothyroxine and liothyronine: a randomized, double blind, cross-over study in thyroidectomized patients. [2010]
Objective To characterize the pharmcodynamic equivalence of L-T3 and L-T4... CONCLUSIONS: This is the first study addressing the equivalency between L-T3 and

Efficacy of combined levothyroxine and liothyronine as compared with levothyroxine monotherapy in primary hypothyroidism: a randomized controlled trial. [2009]
OBJECTIVES: To examine the efficacy of combination therapy with levothyroxine and liothyronine in improvement of general health, psychological problems, and metabolic status in primary hypothyroidism... CONCLUSIONS: The data do not support the hypothesis that combined therapy improves the well-being and general health of patients.

Combined treatment with sertraline and liothyronine in major depression: a randomized, double-blind, placebo-controlled trial. [2007.06]
BACKGROUND: Antidepressant treatments that achieve a higher remission rate than those currently available are urgently needed. The thyroid hormone triiodothyronine may potentiate antidepressant effects. OBJECTIVE: To determine the antidepressant efficacy and safety of liothyronine sodium (triiodothyronine) when administered concurrently with the selective serotonin reuptake inhibitor sertraline hydrochloride to patients with major depressive disorder... CONCLUSIONS: These results demonstrate enhancement of the antidepressant effect of sertraline by concurrent treatment with liothyronine without a significant increase in adverse effects. The antidepressant effect of liothyronine may be directly linked to thyroid function.

more studies >>

Clinical Trials Related to Triostat (Liothyronine)

Liothyronine (T3) for Bipolar Depression [Recruiting]
This study evaluates the efficacy of the thyroid hormone T3 for depression in patients with bipolar disorder. In this study patients will be randomized to receive T3 or placebo.

Liothyronine and Heart Failure. The Long Term Effect of Liothyronine on Left Ventricular Ejection Fraction (LVEF) [Recruiting]
Purpose: The purpose of the study is to examine if treatment with liothyronine increases left ventricular ejection fraction (LVEF) in patients with stable, chronic heart failure.

Acceleration and Relapse Prevention With Triiodothyronine (T3) as an Adjunct to Electroconvulsive Therapy (ECT) [Recruiting]
The purpose of this study is:

- To evaluate liothyronine (Cytomel) as an accelerating agent (i. e. faster rate to

clinical remission) to electroconvulsive therapy.

- To evaluate whether thyroid supplement acceleration can reduce the neurocognitive side

effect of ECT treatment.

- To evaluate whether thyroid status at the time of remission is associated with

subsequent relapse rate.

- To evaluate genetic polymorphisms in enzymes responsible for thyroid metabolism and the

serotonin transporter promoter gene in depression (5-HTTLRP).

Augmentation of the Antidepressant Action of Sertraline With Triiodothyronine (T3)and Reboxetine: Clinical Efficacy, Adverse Effects and Predictors of Response. [Recruiting]

In this project we aim to further refine indications for the use of the thyroid hormone - T3

for patients suffering from depression. We aim to identify a sub-group of patients who are more likely to respond to T3 and establish the time in the treatment course when T3 should be added. The results of this project could have significant, direct clinical implications.

Study of Triostat in Infants During Heart Surgery [Recruiting]
This is a study to determine the safety and efficacy of liothyronine sodium/triiodothyronine (Triostat), a synthetic thyroid hormone, when given to infants with congenital heart disease during cardiopulmonary bypass surgery.

more trials >>


Page last updated: 2013-02-10

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014